US Stem Cell (US Stem Cell) Total Inventories : $0.00 Mil (As of Dec. 2022)

View and export this data going back to 2008. Start your Free Trial

What is US Stem Cell Total Inventories?

US Stem Cell's total inventories for the quarter that ended in Dec. 2022 was $0.00 Mil. US Stem Cell's average total inventories from the quarter that ended in Sep. 2022 to the quarter that ended in Dec. 2022 was $0.00 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. US Stem Cell's Net-Net Working Capital per share for the quarter that ended in Dec. 2022 was $-0.02.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. US Stem Cell's Days Inventory for the three months ended in Dec. 2022 was 18.25.

Inventory Turnover measures how fast the company turns over its inventory within a year. US Stem Cell's Inventory Turnover for the quarter that ended in Dec. 2022 was 5.00.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. US Stem Cell's Inventory-to-Revenue for the quarter that ended in Dec. 2022 was 0.05.

US Stem Cell Total Inventories Historical Data

The historical data trend for US Stem Cell's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

US Stem Cell Total Inventories Chart

US Stem Cell Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Inventories

Get a 7-Day Free Trial

0.09

0.01

US Stem Cell Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Total Inventories	Get a 7-Day Free Trial															-	-	-	-	-

US Stem Cell Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

US Stem Cell (OTCPK:USRM) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

US Stem Cell's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2022 is

	Net-Net Working Capital Per Share (Q: Dec. 2022 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(0.005	+	0.75 * 0.004	+	0.5 * 0.001	-	14.813
-	0	-	0)	/	634.403
=	-0.02

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

US Stem Cell's Days Inventory for the three months ended in Dec. 2022 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Dec. 2022 )	/	Cost of Goods Sold (Q: Dec. 2022 )	*	Days in Period
	=	0.001	/	0.005	*	365 / 4
	=	18.25

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

US Stem Cell's Inventory Turnover for the quarter that ended in Dec. 2022 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Dec. 2022 )	/	Average Total Inventories (Q: Dec. 2022 )
	=	0.005	/	0.001
	=	5.00

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

US Stem Cell's Inventory to Revenue for the quarter that ended in Dec. 2022 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Dec. 2022 )	/	Revenue (Q: Dec. 2022 )
	=	0.001	/	0.02
	=	0.05

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

US Stem Cell Total Inventories Related Terms

Thank you for viewing the detailed overview of US Stem Cell's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

US Stem Cell (US Stem Cell) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » US Stem Cell Inc (OTCPK:USRM) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

N/A

Address

1560 Sawgrass Corporate Parkway, 4th Floor, Sunrise, FL, USA, 33323

Website

http://www.us-stemcell.com

US Stem Cell Inc is a biotechnology company engaged in the discovery and development of autologous cell therapies for the treatment of chronic and acute heart damage. Its product includes MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The company's discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.

Executives

Murphy William P Jr	director	13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325
Gregory Knutson	director	14855 ABERDEN STREET NE, HAM LAKE MN 55304
Mark P Borman	director	5240 WASHBURN AVENUE SOUTH, MINNEAPOLIS MN 55410
Charles A Hart	director	19345 RHINESTONE STREET NW, ANOKA MN 55303
Sheldon T. Anderson	director	1121 CRANDON BLVD., APT. D-103, KEY BISCAYNE FL 33149
Kristin C Comella	officer: Chief Science Officer	1310 LEEWARD WAY, WESTON FL 33327
A Jones Lee	director	54 LOCKE LAKE RD, FRIDLEY MN 55432
Karl Groth	director	1160 FIFTH AVENUE, SUITE 207, NEW YORK NY 10029
Matthew J Fendrich	officer: Vice President,Sales&Marketing	482 PEACOCK LANE SOUTH, JUPITER FL 33458
Alan P Timmins	director	1111 MAIN STREET, SUITE 600, VANCOUVER WA 98660
Bruce C Carson	director	11850 COTTONWOOD STREET NW, COON RAPIDS MN 55448
Howard J Leonhardt	director, 10 percent owner, officer: Executive Chairman & CTO	13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325
Bromley R Scott	officer: VP of Public Relations	13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325
Richard Iii Spencer	director	13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325
Mike Tomas	director	13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325